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ABSTRACT: Background. The aim of this report was to present a rare
case of an adolescent with multinodular goiter (MNG) found to have a
DICER1 mutation.
Methods and Results. The methodology includes a presentation and
discussion of a chart review including endocrine hormone tests, thyroid
ultrasound, and genetic testing for DICER1. A 12-year-old girl presented
with a diffusely enlarged thyroid gland. Family history revealed an older
sister with a history of bilateral ovarian Sertoli-Leydig cell tumors and
MNG. Thyroid function tests were normal. Serial thyroid ultrasounds
showed enlarging multiple bilateral nodules. Fine-needle aspiration
suggested MNG. Genetic testing revealed a novel heterozygous
premature termination mutation (c.1525C>T p.R509X) in the DICER1
gene.
Conclusions. Thyroid nodules are rare in children but carry a higher risk
for malignancy. It is essential to inquire about family history and refer for
genetic evaluation with a family history of MNG. In patients with DICER1
mutations, tumor surveillance is critical due to the increased risk of
multiple tumors, including ovarian tumors and pleuropulmonary blastoma.
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INTRODUCTION
Multinodular goiter (MNG) is a common disorder charac-
terized by non-neoplastic enlargement of the thyroid
gland due to the development of multiple nodules. MNG
is noted to have a greater incidence in females (5:1 ratio
of females:males) and in low iodine intake regions.1
However, the incidence of MNG is still quite common in
regions of sufficient iodine intake, supporting the notion
of a possible genetic basis for this disorder.2 Two loci for
familial MNG have been identified: MNG1 on chromo-
some 14q and MNG2 on chromosome X.3,4 Germline
mutations in DICER1, on chromosome 14q32, have been
linked to familial MNG with and without ovarian Sertoli-
Leydig cell tumors (SLCTs).5
DICER1 is a member of the ribonuclease IIII (RNase
III) family of genes involved in the generation of micro-
RNAs (miRNAs). miRNAs are a class of short, double-
stranded, noncoding regulatory RNAs that modulate gene
expression post-transcriptionally.6 A global downregula-
tion of miRNAs has been shown to promote tumorigene-
sis.7 DICER1 and other miRNAs have been implicated as
having a critical role(s) in the molecular regulation of
multiple organ systems. The importance of DICER1 was
emphasized in a study of Dicer1 knockout mice, which
showed that a null mutation of Dicer1 is embryologically
lethal.8 Tissue-specific conditional knockout experiments
have demonstrated the essential organogenetic role of
Dicer1 in multiple organ systems, including the lung,9 ad-
renal cortex and testis,10 female reproductive system,11
retina,12 glomerulus,13,14 limb,15 and skeletal muscle.16
Jacks and colleagues17 found that heterozygous loss of
Dicer1 accelerated tumor formation in Kras-induced
mouse models of cancer and provided evidence for an
active selection against complete loss of Dicer1 during
tumor progression in these tumors, implicating Dicer1 as
a haploinsufficent tumor suppressor gene.17 Germline
mutations of DICER1 have not only been reported in
MNG with and without Sertoli-Leydig cell tumors, but
also in pleuropulmonary blastoma (PPB), cystic nephroma
(CN), cervix embryonal rhabdomyosarcoma (cERMS),
primitive neuroectodermal tumor (cPNET), and Wilms
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tumor.18–22 DICER1 mutations exhibit low penetrance in
PPB and CN, but high penetrance in MNG.5 We report 2
siblings with MNG and a germline DICER1 mutation, in
which the older sibling also manifested bilateral SLCTs.
CASE REPORTS
This study was approved by the University of Michigan
Institutional Review Board committee. A chart review
was performed for both siblings.
The otolaryngology, genetic, and endocrinology evalua-
tions as well as the CT scan, thyroid ultrasound, and
endocrine hormone tests were performed at the University
of Michigan (Ann Arbor, MI). The gynecologic evalua-
tion, pelvic ultrasound, chest CT, and CA-125 laboratory
tests were performed at the National Institutes of Health
(Bethesda, MD). DICER1 sequence analysis was per-
formed at Ambry Genetics Laboratory (Aliso Viejo, CA).
Sibling 1
A 12-year-old girl was noticed to have an enlarged thy-
roid earlier in January 2011. History was negative for
symptoms of hypothyroidism or hyperthyroidism, includ-
ing palpitation, sweating, nervousness, tremor, diarrhea,
insomnia, cold or heat intolerance, fatigue, constipation,
or hair loss. She reported a recent 4-pound weight loss
attributed to increased physical activity. She had no signs
of hyperandrogenism such as hirsutism, excessive acne,
or excessive hair loss. She had regular menses. The
patient was evaluated by a pediatric otolaryngologist, a
pediatric endocrinologist, and a pediatric geneticist.
Her birth history was unremarkable without teratogenic
exposures. Her past medical history was significant for
eustachian tube dysfunction and right tympanic mem-
brane perforation status post right paper patch myringo-
plasty. She also underwent surgical excision of a midline
neck mass at age 6; pathologic examination was consist-
ent with dermoid cyst.
Family history was significant for colon cancer in a
paternal grandfather, esophageal cancer in a paternal
great uncle, and possible thyroid disorders in a grand-
mother and a great aunt. Furthermore, the patient’s sister
had a significant oncologic history (see Sibling 2, below).
Physical examination was notable for a small right tym-
panic membrane perforation and a thyroid gland with dif-
fuse slight enlargement without discrete palpable nodules.
The rest of the head and neck examination was normal.
Thyroid ultrasound showed a right thyroid lobe meas-
uring 4.2  1.5  1 cm and a left thyroid lobe measuring
4.5  1.9  1.7 cm. Three complex cystic lesions were
noted, 1 within the isthmus (approximately 1.6  1  1.9
cm) and 2 in the left lobe measuring approximately 1.2 
1.1 and 1.6  1.2 cm. In addition, there was a nonspe-
cific 5-mm echogenic right lobe lesion. In summary, the
ultrasound was consistent with a multinodular goiter,
without suspicious calcifications or appreciable internal
vascularity. Subsequent thyroid ultrasound 9 months later
showed a right thyroid lobe measuring 4.5  1.6  1.8
cm, with the largest nodule in the right thyroid measuring
1.7  1.2  1.1 cm. The left thyroid lobe measured 4.1
 2.2  1.9 cm with the 2 largest nodules in the left
measuring 1.6  1.4  1.2 (superior pole) and 1.5  1.5
 1.2 cm (inferior pole). The solid portions of multiple
nodules demonstrated internal vascularity, and many of
the nodules had enlarged. Fine-needle aspiration showed
benign follicular cells, colloid and histiocytes, consistent
with multinodular goiter.
Transabdominal pelvic ultrasound showed a uterus
measuring 3.6  2.8  6.7 cm, with an endometrial
thickness of 5 mm. The right ovary was 2.75  1.3 
3.03 cm, with a 1.8-cm cyst, and the left ovary was 2.13
 1.33  2.29 cm, with no fluid seen in the endometrial
canal or cul-de-sac and no evidence of uterine fibroids.
Chest CT showed bilateral pleuropulmonary blebs and a
nonspecific 3-mm right pleural-based nodule. The pleuro-
pulmonary blebs needed further workup to rule out type I
pleuropulmonary blastomas.
Laboratory test results including thyroid-stimulating
hormone (TSH), free T4, thyroid-stimulating immuno-
globulin, thyroid peroxidase antibodies, alpha fetoprotein
(AFP) tumor marker, serum total testosterone levels,
dehydroepiandrosterone sulfate (DHEA-S), and b-HCG
tumor markers were all normal. Genetic testing showed a
novel heterozygous premature termination mutation
(c.1525C>T p.R509X) in the DICER1 gene.
Sibling 2
The 23-year-old sister of sibling 1 has also been fol-
lowed at our institution for postsurgical hypothyroidism
and SLCT. She initially presented with abdominal disten-
tion and abdominal pain at 8 years of age. A CT scan
revealed a left ovarian mass for which she underwent left
oophorectomy and omentectomy. Pathology revealed a
Sertoli-Leydig cell tumor of intermediate differentiation.
Testosterone level was not obtained at that time, and she
did not have hirsutism. She had her menarche at 11 years
of age.
At 14 years of age, sibling 2 was found to have an
enlarged thyroid gland. Thyroid ultrasound and scan
revealed a cold nodule of the left thyroid gland and the
absence of a right thyroid lobe, consistent with unilateral
agenesis. Hemithyroidectomy (functional total thyroidec-
tomy) was eventually performed. The pathology showed
multiple benign nodules indicating a multinodular goiter.
Furthermore, at 14 years of age, she had hirsutism and
irregular menses without excessive weight gain. The tes-
tosterone level was increased to 68 ng/dL (normal range,
20–38). A CT scan revealed a new right-sided ovarian
mass. She underwent right oophorectomy and bilateral
salpingectomy. The mass was also identified to be an
SLCT of intermediate differentiation that was thought
to be asynchronous and an independent primary tumor.
She therefore did not receive chemotherapy, although
10% of intermediate differentiated tumors are clinically
malignant. She was started on levothyroxine sodium
(Levoxyl) and the Ortho Evra birth-control patch
(McNeil-PPC, Inc., New Brunswick, NJ) for hormone
replacement. The family moved to Michigan and trans-
ferred her endocrine care to our institution when she
was 15 years of age.
DISCUSSION
Current recommendations for the management of non-
toxic MNG are based on the fact that it carries a risk for
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thyroid cancer similar to that of a solitary thyroid nodule,
approximately 1% to 5%.23,24 To date, thyroid cancer has
not been reported in DICER1 syndrome. However, new
guidelines for MNG management are warranted, given
recent advancements in the genetic cause for this disor-
der. Most cases of "MNG" referred to endocrine clinics
are more often due to conditions of autoimmunity, such
as Hashimoto’s thyroiditis and not true MNG. Careful
interpretation of the sonographic findings is paramount.
Hyperthyroidism associated with toxic MNG warrants
treatment. Occasionally, toxic MNG may be associated
with McCune-Albright syndrome. If the patient indeed
has true MNG without abnormality in thyroid function
and without thyroid autoimmunity, a thorough inquiry
into the family oncologic history and monitoring of tumor
markers are warranted. We believe measurement of tes-
tosterone, DHEA/DHEA-S, AFP, b-HCG, and CA-125
levels along with TSH, free T4, and T3 should be per-
formed annually or sooner if signs or symptoms warrant.
Our patient has a heterozygous mutation in DICER1,
which is most likely the reason for her MNG. The father
and older sister were tested at an outside institution and
found to carry the familial DICER1 mutation first identi-
fied in the younger sister at our institution. Consequently,
the clinical phenotype of the older sister is consistent
with her molecular result. To date, no comprehensive
guidelines are available for tumor surveillance in this new
syndrome. Due to our patient’s mutation and her family
history of tumors, close monitoring is warranted.
Most DICER1 mutations noted in patients with PPB
were predicted to result in truncated proteins.20,26 Rio
Frio et al5 noted 3 mutations that were nontruncating with
high penetrance for MNG. The nonsense DICER1 muta-
tion in codon 509 in our patient most likely results in a
truncated protein. Thus, although penetrance is low, our
patient underwent a chest CT showing 2 small cystic
lesions. Analysis of germline DICER1 mutations from a
large series of probands with differentiated thyroid cancer
with and without MNG showed no correlation between
the DICER1 mutation and thyroid carcinoma.5 Because
DICER1 mutations have not been associated with thyroid
carcinoma to date, and our patient is asymptomatic, surgi-
cal intervention is currently not recommended. In addi-
tion, we recommend tumor surveillance for our patient
for SLCT via laboratory and annual ultrasound.
Our report stresses the importance of a thorough inquiry
into the family oncologic history in patients who have mul-
tinodular goiter without abnormality in thyroid function
and without thyroid autoimmunity. Genetic testing is war-
ranted for patients with a family history of cold multinodu-
lar goiter and/or ovarian Sertoli-Leydig cell tumors.
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